 WOBURN, Mass., July 07, 2021 GLOBE NEWSWIRE -- Replimune Group, Inc. NASDAQ: REPL, a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that Robert Coffin, Ph.D., President and Chief Research Development Officer of Replimune, will participate in a panel titled Novel Mechanisms and Strategies for Addressing PD-L1 RefractoryResistant Tumors at the William Blair Biotech Focus Conference 2021 taking place virtually on Wednesday, July 14, 2021 at 4:20 PM ET. 